B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
暂无分享,去创建一个
D. Hilbert | D. Nemazee | W. Stohl | A. Gavin | T. Migone | C. Collins
[1] A. Steinberg,et al. Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. , 2010, Arthritis and rheumatism.
[2] D. Hilbert,et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. , 2006, Arthritis and rheumatism.
[3] M. Pelletier,et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.
[4] C. Putterman,et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. , 2005, Arthritis and rheumatism.
[5] V. Roschke,et al. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. , 2005, Blood.
[6] Ehrenstein,et al. Serological changes following B cell depletion therapy in Systemic Lupus Erythematosus: Relationship with BLyS , 2004 .
[7] K. E. Schwartz,et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. , 2004, Arthritis and rheumatism.
[8] T. Phan,et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. , 2004, Immunity.
[9] J. Cyster,et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. , 2004, Immunity.
[10] M. Scott,et al. Cutting Edge: BAFF Regulates CD21/35 and CD23 Expression Independent of Its B Cell Survival Function , 2004, The Journal of Immunology.
[11] V. Roschke,et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. , 2003, Arthritis and rheumatism.
[12] C. Ware,et al. ΔBAFF, an Alternate Splice Isoform That Regulates Receptor Binding and Biopresentation of the B Cell Survival Cytokine, BAFF* , 2003, Journal of Biological Chemistry.
[13] S. Tangye,et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. , 2003, The Journal of clinical investigation.
[14] I. Maclennan,et al. NF-κB1 p50 Is Required for BLyS Attenuation of Apoptosis but Dispensable for Processing of NF-κB2 p100 to p52 in Quiescent Mature B Cells1 , 2003, The Journal of Immunology.
[15] Karin Reiter,et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.
[16] V. Roschke,et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. , 2003, Arthritis and rheumatism.
[17] B. Nardelli,et al. G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS , 2003, The Journal of experimental medicine.
[18] D. Isenberg,et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.
[19] D. Seshasayee,et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. , 2002, Immunity.
[20] J. Kearney,et al. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. , 2002, Immunity.
[21] B. Nardelli,et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL , 2002, Nature Immunology.
[22] D. Hilbert,et al. Cutting Edge: BLyS Enables Survival of Transitional and Mature B Cells Through Distinct Mediators1 , 2002, The Journal of Immunology.
[23] D. Hilbert,et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers , 2001, Current Biology.
[24] M. Scott,et al. An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway , 2001, Science.
[25] S. Dillon,et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. , 2001, Immunity.
[26] V. Roschke,et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. , 2001, Arthritis and rheumatism.
[27] G. Alarcón,et al. Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus1 , 2001, The Journal of Immunology.
[28] J. Tschopp,et al. Baff Mediates Survival of Peripheral Immature B Lymphocytes , 2000, The Journal of experimental medicine.
[29] P. Lipsky,et al. Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus1 , 2000, The Journal of Immunology.
[30] M. Tourigny,et al. Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response , 2000, The Journal of experimental medicine.
[31] J. Tschopp,et al. Baff Binds to the Tumor Necrosis Factor Receptor–Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population , 2000, The Journal of experimental medicine.
[32] Don Foster,et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.
[33] D. Lacey,et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Tschopp,et al. Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.
[35] Amy S Orr,et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.
[36] J. Tschopp,et al. BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.
[37] Leslie J. Crofford,et al. Primer on the Rheumatic Diseases , 1999 .
[38] D. Sackett,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.
[39] B. Doft,et al. Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE. , 1977, Arthritis and rheumatism.
[40] V. Roschke,et al. Proinflammatory mediators elicit the secretion of the intracellular B- lymphocyte stimulator (BLyS) pool that is stored in activated neutrophils: implications for inflammatory diseases. Short Title: Inducible BLyS secretion by activated neutrophils , 2004 .
[41] P. Moore,et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. , 2001, Blood.
[42] P. Lipsky,et al. Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus. , 1979, Clinical and experimental immunology.